View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 27, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
------------------------------------------------------
Delaware 0-12957 22-237286
-------- ------- ---------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
Item 5. Other Events
- ------- ------------
Enzon, Inc. ("Enzon" or the "Company") announced that it has
selected Medac GmbH (MEDAC) as its marketing partner in Europe and Russia for
ONCASPAR (Registered Trademark). ONCASPAR is Enzon's oncology product now being
sold in the U.S. for the indication of acute lymphoblastic leukemia (ALL) for
patients who are hypersensitive to native forms of asparaginase. MEDAC,
headquartered in Hamburg, Germany, develops and markets anti- cancer,
anti-coagulant and diagnostic products. MEDAC will buy ONCASPAR from Enzon at a
set price which increases over the term of the agreement. The agreement also
contains escalating minimum annual purchase requirements. Additionally, MEDAC
will be responsible to obtain registrations for ONCASPAR in the remaining
European countries where it is not yet approved, market the product in Europe
and Russia, and conduct clinical trials in Europe for front line use and
additional indications including non-Hodgkin's lymphoma, adult ALL, chronic
lymphocytic leukemia (CLL) and AIDS related lymphoma. MEDAC has an extensive
sales base in Germany where ONCASPAR is already approved, as well as marketing
capabilities throughout the rest of Europe and Russia. In particular, MEDAC has
extensive sales experience with the leukemia market in Europe. Native
asparaginase is currently sold in Europe as a treatment for not only pediatric
ALL, but also for adult ALL, non-Hodgkin's lymphoma and other indications.
- 2 -
Enzon also announced that it has successfully completed the transfer of
know-how for the manufacture of PEG-INTRON A to Schering Corporation
("Schering"), a subsidiary of Schering-Plough Corporation, and has received a
payment of $1 million. In 1995, Schering and Enzon amended their existing
agreement to include the transfer of Enzon's PEG-INTRON A know-how and worldwide
manufacturing rights to Schering for $3 million, of which $2 million was paid
last year. At that time, Schering invested $2 million in Enzon's common stock.
Enzon retained the option to be Schering's exclusive manufacturer of the product
for the U.S. market.
- 3 -
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: November 4, 1996
ENZON, INC.
-----------
(Registrant)
By: /s/ KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer
- 4 -